Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway

Dong,Meng‑Hua; Zhang,Qian; Wang,Yuan‑Yuan; Zhou,Bai‑Sui; Sun,Yu‑Fei; Fu,Qiang

doi:10.3892/etm.2016.3061

Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway

Authors:
- Meng‑Hua Dong
- Qian Zhang
- Yuan‑Yuan Wang
- Bai‑Sui Zhou
- Yu‑Fei Sun
- Qiang Fu
View Affiliations

Affiliations: College of Basic Medicine, Binzhou Medical University, Yantai, Shandong 264003, P.R. China, Department of Oncology, Linyi People's Hospital, Linyi, Shandong 276003, P.R. China, Department of Bone and Joint Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong 264003, P.R. China
Published online on: February 9, 2016 https://doi.org/10.3892/etm.2016.3061
Pages: 1475-1480

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Euphorbia fischeriana Steud, a traditional Chinese medicine, has been shown to inhibit the growth of various cancers by the induction of apoptosis and cell cycle arrest. The purpose of the present study was to investigate the association between the phosphoinositide‑3‑kinase (PI3K)/protein kinase B (Akt) signaling pathway and the inhibitory effect of Euphorbia fischeriana Steud on the growth and metastasis of melanoma B16 cells in vitro, and the underlying mechanisms. MTT assay results indicated that Euphorbia fischeriana Steud inhibited the growth of B16 cells in a time- and dose-dependent manner. Flow cytometric analysis revealed that Euphorbia fischeriana Steud markedly induced apoptosis of the B16 cells, with arrest at the G0/G1 phase of the cell cycle. In addition, in a Transwell assay Euphorbia fischeriana Steud significantly suppressed the migration of B16 cells. Western blot analysis revealed that the expression levels of phosphatase and tensin homolog (PTEN) were upregulated, and the phosphorylation of Akt was downregulated, which resulted in inhibition of the PI3K/Akt signaling pathway and the eventual suppression of its downstream targets, such as matrix metalloproteinase‑2 mRNA, in B16 cells. The results demonstrated that Euphorbia fischeriana Steud inhibited the growth and migration of B16 cells, possibly via modulation of the PI3K/Akt signaling pathway and upregulation of PTEN expression levels, in addition to downregulation of p-Akt expression. The aforementioned findings suggest that Euphorbia fischeriana Steud may have broad therapeutic applications in the treatment of malignant melanoma.

View Figures

View References

1	Tsao H, Chin L, Garraway LA and Fisher DE: Melanoma: From mutations to medicine. Genes Dev. 26:1131–1155. 2012. View Article : Google Scholar : PubMed/NCBI
2	Mateus C and Robert C: Major therapeutic advances in the treatment of metastatic melanoma. Bull Cancer. 99:619–625. 2012.(In French). PubMed/NCBI
3	Rosenberg E, Horev A and Neulander EZ: Amelanotic malignant melanoma of the penis. A case report and literature review. Arch Ital Urol Androl. 84:42–43. 2012.PubMed/NCBI
4	Mikhnin AE, Tarkov SA and Frolova OS: Cutaneous melanoma in the head and neck region: Current knowledge. Vopr Onkol. 58:19–25. 2012.(In Russian). PubMed/NCBI
5	Grossmann AH, Grossmann KF and Wallander ML: Molecular testing in malignant melanoma. Diagn Cytopathol. 40:503–510. 2012. View Article : Google Scholar : PubMed/NCBI
6	Kaufman HL: Vaccines for melanoma and renal cell carcinoma. Semin Oncol. 39:263–275. 2012. View Article : Google Scholar : PubMed/NCBI
7	Lacy KE, Karagiannis SN and Nestle FO: Advances in the treatment of melanoma. Clin Med. 12:168–171. 2012. View Article : Google Scholar
8	Bloomfield JG and Tanay MA: Chemotherapy in the community: The importance of patient assessment. Br J Community Nurs. 17:278–283. 2012. View Article : Google Scholar : PubMed/NCBI
9	Sun YX and Liu JC: Chemical constituents and biological activities of Euphorbia fischeriana Steud. Chem Biodivers. 8:1205–1214. 2011. View Article : Google Scholar : PubMed/NCBI
10	Wang YB, Huang R, Wang HB, Jin HZ, Lou LG and Qin GW: Diterpenoids from the roots of Euphorbia fischeriana. J Nat Prod. 69:967–970. 2006. View Article : Google Scholar : PubMed/NCBI
11	Smith ME and Bauer-Wu S: Traditional chinese medicine for cancer-related symptoms. Semin Oncol Nurs. 28:64–74. 2012. View Article : Google Scholar : PubMed/NCBI
12	Liu J, Li X, Liu J, Ma L, Li X and Fønnebø V: Traditional chinese medicine in cancer care: A review of case reports published in Chinese literature. Forsch Komplementmed. 18:257–263. 2011. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Tremante E, Ginebri A, Lo Monaco E, Frascione P, Di Filippo F, Terrenato I, Benevolo M, Mottolese M, Pescarmona E and Visca P: Melanoma molecular classes and prognosis in the postgenomic era. Lancet Oncol. 13:e205–e211. 2012. View Article : Google Scholar : PubMed/NCBI
15	Espinosa E, Berrocal A, López Martín JA, González Cao M, Cerezuela P, Mayordomo JI and Martín Algarra S: Grupo Español de Melanoma (GEM): Advances in cutaneous melanoma. Clin Transl Oncol. 14:325–332. 2012. View Article : Google Scholar : PubMed/NCBI
16	Sanford M: Ipilimumab: In previously treated patients with advanced melanoma. Bio Drugs. 26:185–193. 2012.
17	Trinh VA and Hwu WJ: Ipilimumab in the treatment of melanoma. Expert Opin Biol Ther. 12:773–782. 2012. View Article : Google Scholar : PubMed/NCBI
18	Stratigos AJ, Forsea AM, van der Leest RJ, de Vries E, Nagore E, Bulliard JL, Trakatelli M, Paoli J, Peris K, Hercogova J, et al: Euromelanoma: A dermatology-led European campaign against nonmelanoma skin cancer and cutaneous melanoma. Past, present and future. Br J Dermatol. 167:99–104. 2012. View Article : Google Scholar : PubMed/NCBI
19	Smalley KS and McArthur GA: The current state of targeted therapy in melanoma: This time it's personal. Semin Oncol. 39:204–214. 2012. View Article : Google Scholar : PubMed/NCBI
20	Mathew R and Messina JL: Recent advances in pathologic evaluation and reporting of melanoma. Semin Oncol. 39:184–191. 2012. View Article : Google Scholar : PubMed/NCBI
21	Silva E: Adjunct primer for the use of national comprehensive cancer network guidelines for the surgical management of cutaneous malignant melanoma patients. World J Surg Oncol. 6:542012. View Article : Google Scholar
22	Flaherty KT, Hodi FS and Fisher DE: From genes to drugs: Targeted strategies for melanoma. Nat Rev Cancer. 12:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
23	Aguissa-Touré AH and Li G: Genetic alterations of PTEN in human melanoma. Cell Mol Life Sci. 69:1475–1491. 2012. View Article : Google Scholar : PubMed/NCBI
24	Wu H, Goel V and Haluska FG: PTEN signaling pathways in melanoma. Oncogene. 22:3113–3122. 2003. View Article : Google Scholar : PubMed/NCBI
25	Madhunapantula SV and Robertson GP: The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 22:400–419. 2009. View Article : Google Scholar : PubMed/NCBI
26	Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, Li G and Herlyn M: The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci. 10:2986–3001. 2005. View Article : Google Scholar : PubMed/NCBI
27	Davies MA: The role of the PI3K-AKT pathway in melanoma. Cancer J. 18:142–147. 2012. View Article : Google Scholar : PubMed/NCBI
28	Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P and Bouscary D: PI3K and mTOR signaling pathways in cancer: New data on targeted therapies. Curr Oncol Rep. 14:129–138. 2012. View Article : Google Scholar : PubMed/NCBI
29	Bartholomeusz C and Gonzalez-Angulo AM: Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:121–130. 2012. View Article : Google Scholar : PubMed/NCBI
30	Chen Y, Wang BC and Xiao Y: PI3K: A potential therapeutic target for cancer. J Cell Physiol. 227:2818–2821. 2012. View Article : Google Scholar : PubMed/NCBI
31	Zhu B and Zhou X: The study of PI3K/AKT pathway in lung cancer metastasis and drug resistance. Zhongguo Fei Ai Za Zhi. 14:689–694. 2011.(In Chinese). PubMed/NCBI
32	Lin H, Liu J and Zhang Y: Developments in cancer prevention and treatment using traditional chinese medicine. Front Med. 5:127–133. 2011. View Article : Google Scholar : PubMed/NCBI
33	Wang JY, Xu L, Zhang RX and Lao L: Traditional chinese medicine for cancer pain. Zhong Xi Yi Jie He Xue Bao. 9:129–134. 2011.(In Chinese). View Article : Google Scholar : PubMed/NCBI
34	Zhou TX, Bao GH, Ma QG, Che CT, Lv Y, Wang C and Zheng QT: Langduin C, a novel dimeric diterpenoid from the roots of Euphorbia fischeriana. Tetrahedron Lett. 44:135–137. 2003. View Article : Google Scholar
35	Wang JH, Zhang K, Niu HY, Shu LH, Yue DM, Li D and He P: Jolkinolide B from Euphorbia fischeriana Steud induces in human leukemic cells apoptosis via JAK2/STAT3 pathways. Int J Clin Pharmacol Ther. 51:170–178. 2013. View Article : Google Scholar : PubMed/NCBI
36	Pon D, Wang Z, Le KN and Chow MS: Harnessing traditional Chinese medicine to improve cancer therapy: Issues for future development. Ther Deliv. 1:335–344. 2010. View Article : Google Scholar : PubMed/NCBI